Welcome to our dedicated page for ACLARION SEC filings (Ticker: ACONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for a fast way to decode how Aclarion funds its Nociscan MR spectroscopy platform or when executives exercise their ACONW warrants? Most investors start by asking where to find Aclarion insider trading Form 4 transactions or how to read an Aclarion annual report 10-K simplified. This page brings every SEC disclosure into one place and answers those questions up front.
Our AI engine turns dense documents into concise insights: understanding Aclarion SEC documents with AI means you can skim a summary instead of 200 pages. New filings flow in directly from EDGAR, so Aclarion Form 4 insider transactions real-time and each Aclarion 8-K material events explained alert appear minutes after submission.
Wondering what to open first?
- 10-K & 10-Q – The Aclarion quarterly earnings report 10-Q filing details cash burn, clinical-trial spend, and SaaS revenue growth, while our Aclarion earnings report filing analysis highlights key metrics.
- Form 4 – Track Aclarion executive stock transactions Form 4 to gauge insider confidence before pivotal trial results.
- DEF 14A – The Aclarion proxy statement executive compensation section explains how leadership is incentivized to hit commercialization milestones.
Every filing is paired with plain-language commentary, AI-powered red-flag detection, and keyword search so Aclarion SEC filings explained simply becomes reality. Whether you monitor warrant dilution scenarios or need an at-a-glance view of clinical data disclosures, Stock Titan delivers the information you need, when you need it.
Aclarion, Inc. reported results for the quarter ended June 30, 2025. Cash and cash equivalents were $12,850,657 (including $11,949,908 in money market funds), which management believes funds operations into the third quarter of 2026. Revenue grew to $19,319 in Q2 2025 (up 76% year-over-year) and $38,309 for the six months (up 82%), driven by increased NOCISCAN report volume in the U.K. Q2 gross profit was $5,140, but operating expenses rose to $1.74 million, producing a Q2 net loss of $1.60 million and a six-month net loss of $3.64 million. In H1 2025 the company raised approximately $20.1 million via a public unit offering, two registered direct offerings and warrant exercises. Corporate actions included two 2025 reverse stock splits and the $1,213,590 redemption of Series B preferred stock. The company recorded a $687,500 settlement in March 2025. Readers should consult the full notes for detailed terms of warrants, preferred conversions, and cash assumptions.
FAQ
What is the current stock price of ACLARION (ACONW)?
